DaVita is presenting seven new studies at ASN Kidney Week 2026, highlighting advances in dialysis innovation, home-based treatments, and patient perspectives. These studies emphasize improved middle molecule clearance and real-world clinical evidence to support emerging kidney therapies. This research aims to help clinicians make informed decisions and enhance patient care as new treatments gain traction. DaVita continues to lead in kidney care innovation, serving nearly 300,000 patients globally.
DaVita Inc (DVA) shares are trading at USD 182.50 on Pluang as of Oct 15, 2026 19:42 WIB, showing a 1.00% increase for the day. The company has a market cap of $11.53 billion and a 52-week high of $240.96. Pluang investors currently hold their positions for an average of 114 days, with order activity fully on the buy side.
